JP5026408B2 - 泌尿生殖器癌及びその転移の治療を意図した、亜ヒ酸、そのナトリウム塩、及びその誘導体を含む製薬組成物 - Google Patents

泌尿生殖器癌及びその転移の治療を意図した、亜ヒ酸、そのナトリウム塩、及びその誘導体を含む製薬組成物 Download PDF

Info

Publication number
JP5026408B2
JP5026408B2 JP2008511051A JP2008511051A JP5026408B2 JP 5026408 B2 JP5026408 B2 JP 5026408B2 JP 2008511051 A JP2008511051 A JP 2008511051A JP 2008511051 A JP2008511051 A JP 2008511051A JP 5026408 B2 JP5026408 B2 JP 5026408B2
Authority
JP
Japan
Prior art keywords
cancer
treatment
leukemia
sodium salt
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008511051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008546640A5 (https=
JP2008546640A (ja
Inventor
サン−ボン・イ
ヨン−ジン・ヤン
Original Assignee
コミノックス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コミノックス・インコーポレイテッド filed Critical コミノックス・インコーポレイテッド
Publication of JP2008546640A publication Critical patent/JP2008546640A/ja
Publication of JP2008546640A5 publication Critical patent/JP2008546640A5/ja
Application granted granted Critical
Publication of JP5026408B2 publication Critical patent/JP5026408B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Luminescent Compositions (AREA)
JP2008511051A 2005-05-09 2006-05-09 泌尿生殖器癌及びその転移の治療を意図した、亜ヒ酸、そのナトリウム塩、及びその誘導体を含む製薬組成物 Expired - Fee Related JP5026408B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05076071.9 2005-05-09
EP05076071A EP1721615A1 (en) 2005-05-09 2005-05-09 Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
PCT/KR2006/001731 WO2006121280A1 (en) 2005-05-09 2006-05-09 Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis

Publications (3)

Publication Number Publication Date
JP2008546640A JP2008546640A (ja) 2008-12-25
JP2008546640A5 JP2008546640A5 (https=) 2012-06-14
JP5026408B2 true JP5026408B2 (ja) 2012-09-12

Family

ID=35197739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008511051A Expired - Fee Related JP5026408B2 (ja) 2005-05-09 2006-05-09 泌尿生殖器癌及びその転移の治療を意図した、亜ヒ酸、そのナトリウム塩、及びその誘導体を含む製薬組成物

Country Status (23)

Country Link
US (2) US20090011047A1 (https=)
EP (5) EP1721615A1 (https=)
JP (1) JP5026408B2 (https=)
KR (3) KR20160035101A (https=)
CN (2) CN101277707A (https=)
AR (1) AR054448A1 (https=)
AU (1) AU2006244767B2 (https=)
BR (1) BRPI0608716A2 (https=)
CA (3) CA2840609C (https=)
CY (2) CY1113475T1 (https=)
DK (2) DK1885380T3 (https=)
ES (2) ES2394264T3 (https=)
HU (1) HUE046029T2 (https=)
IL (3) IL187220A (https=)
LT (1) LT3067068T (https=)
PL (2) PL1885380T3 (https=)
PT (1) PT1885380E (https=)
RU (1) RU2401662C2 (https=)
SG (5) SG177983A1 (https=)
SI (2) SI3067068T1 (https=)
TW (5) TWI386214B (https=)
WO (1) WO2006121280A1 (https=)
ZA (1) ZA200710559B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20120045520A1 (en) * 2008-08-21 2012-02-23 Sang Bong Lee Pharmaceutical composition comprising arsenite for the treatment of malignancy
PT2475362T (pt) * 2009-09-10 2019-05-27 Kominox Inc Terapia especifica para celulas estaminais cancerigenas e para 0 cancro resistente a medicamentos
BR112012008310A2 (pt) * 2009-09-18 2017-06-06 Kominox Inc métodos para tratamento de tumores cerebrais
WO2011086137A1 (en) 2010-01-13 2011-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Promyelocytic leukemia protein as a redox sensor
RU2602937C2 (ru) * 2011-01-11 2016-11-20 Универзитет Базель Комбинация сиросингопина и митохондриальных ингибиторов для лечения рака и для иммуносупрессии
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
KR101309844B1 (ko) * 2013-03-15 2013-09-23 박상채 항암 활성 증진용 한약재 및 이의 제조방법
RU2618405C1 (ru) * 2015-12-31 2017-05-03 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ определения продолжительности адъювантной химиотерапии при местно-распространенном колоректальном раке с метастазами в регионарные лимфоузлы после радикальных оперативных вмешательств
US10806768B2 (en) * 2016-05-26 2020-10-20 Stephen N. Pitcher Composition for promoting metallothionein production
ES2964979T3 (es) 2016-12-01 2024-04-10 Eupharma Pty Ltd Composiciones de arsénico
EP3758686B1 (en) 2018-02-26 2024-11-06 R.P. Scherer Technologies, LLC Pharmaceutical dosage form for an emulsion of simethicone and loperamide
AU2019239671B2 (en) * 2018-03-22 2025-02-27 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture
WO2019234112A1 (en) * 2018-06-05 2019-12-12 Katholieke Universiteit Leuven Combination treatment of arsenic oxide and antiandrogens
IL295648A (en) * 2020-02-16 2022-10-01 Komipharm Int Australia Pty Ltd treatment method
KR20220020633A (ko) * 2020-08-12 2022-02-21 이상봉 탈모방지 또는 발모촉진용 주사제 조성물
KR20220020635A (ko) * 2020-08-12 2022-02-21 이상봉 탈모방지 또는 발모촉진용 외용제 조성물
KR20220020637A (ko) * 2020-08-12 2022-02-21 이상봉 항암화학요법이나 방사선요법으로 인한 암 환자의 탈모증을 포함한 탈모증 환자에 대하여 탈모를 방지하고 발모를 촉진하는 메타아르세나이트의 염을 함유하는 경구 투여용 약학적 조성물
CN112336746A (zh) * 2020-10-23 2021-02-09 内蒙古科技大学包头医学院 一种膀胱癌灌注化疗药物及其应用
CN116549741B (zh) * 2022-01-29 2025-04-11 中国科学院上海硅酸盐研究所 一种具有抑癌抗菌作用的表面改性镍钛合金材料及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
FR2431686A1 (fr) 1978-07-20 1980-02-15 Nestle Sa Soc Ass Tech Prod Mecanisme de dosage et d'equilibrage et machine de remplissage comprenant un tel mecanisme
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
KR930001917A (ko) * 1991-07-26 1993-02-22 김두석 악성 종양 치료제의 제조방법
EP0804928B1 (en) * 1994-02-18 2004-10-20 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
RU2035181C1 (ru) * 1994-02-18 1995-05-20 Тамара Васильевна Воробьева Средство для лечения лейкозов и способ лечения лейкозов
JP2001519366A (ja) * 1997-10-15 2001-10-23 ポーラクス バイオファーマシュティカルズ，インコーポレーテッド ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
EP1496918B1 (en) * 2002-04-10 2023-02-08 Komipharm International Co., Ltd. Use of sodium meta-arsenite for the treatment of tumours
KR100632250B1 (ko) * 2004-02-16 2006-10-11 정태호 비소 화합물을 유효성분으로 하는 항암제
US20060104292A1 (en) 2004-11-15 2006-05-18 Gupta Vivek G System and methods for supporting multiple communications interfaces with single client interface
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
PT2475362T (pt) 2009-09-10 2019-05-27 Kominox Inc Terapia especifica para celulas estaminais cancerigenas e para 0 cancro resistente a medicamentos

Also Published As

Publication number Publication date
SI3067068T1 (sl) 2020-02-28
EP2361628A1 (en) 2011-08-31
IL187220A0 (en) 2008-02-09
SI1885380T1 (sl) 2013-01-31
PL1885380T3 (pl) 2013-02-28
TWI386214B (zh) 2013-02-21
SG10201602555WA (en) 2016-05-30
SG175633A1 (en) 2011-11-28
US20090011047A1 (en) 2009-01-08
TW201615200A (zh) 2016-05-01
CN101277707A (zh) 2008-10-01
LT3067068T (lt) 2019-12-10
SG10202100785PA (en) 2021-02-25
EP2762145A1 (en) 2014-08-06
IL229975A0 (en) 2014-01-30
TWI574692B (zh) 2017-03-21
CA2840609A1 (en) 2006-11-16
DK3067068T3 (da) 2019-11-18
KR101413731B1 (ko) 2014-07-10
ES2754372T3 (es) 2020-04-17
TW201500046A (zh) 2015-01-01
AU2006244767B2 (en) 2011-06-16
KR20160035101A (ko) 2016-03-30
IL244728A0 (en) 2016-04-21
TWI522105B (zh) 2016-02-21
CA2926846A1 (en) 2006-11-16
KR20150085122A (ko) 2015-07-22
KR20080030559A (ko) 2008-04-04
CY1113475T1 (el) 2016-06-22
SG177983A1 (en) 2012-02-28
TW201540306A (zh) 2015-11-01
PL3067068T3 (pl) 2020-08-10
EP3067068A1 (en) 2016-09-14
US11464859B2 (en) 2022-10-11
IL187220A (en) 2014-11-30
TWI539957B (zh) 2016-07-01
TW201302208A (zh) 2013-01-16
BRPI0608716A2 (pt) 2010-12-07
HUE046029T2 (hu) 2020-01-28
EP3067068B1 (en) 2019-08-14
RU2007145489A (ru) 2009-06-20
WO2006121280A1 (en) 2006-11-16
AR054448A1 (es) 2007-06-27
CY1122522T1 (el) 2021-01-27
ES2394264T3 (es) 2013-01-30
RU2401662C2 (ru) 2010-10-20
EP1885380B1 (en) 2012-07-11
SG10201405278SA (en) 2015-05-28
CA2840609C (en) 2016-08-16
IL229975A (en) 2017-12-31
CN104758312A (zh) 2015-07-08
JP2008546640A (ja) 2008-12-25
EP1885380A1 (en) 2008-02-13
CA2926846C (en) 2019-04-02
EP1721615A1 (en) 2006-11-15
ZA200710559B (en) 2008-10-29
TW200716144A (en) 2007-05-01
DK1885380T3 (da) 2012-10-22
CA2608035C (en) 2015-02-17
US20160199411A1 (en) 2016-07-14
EP1885380A4 (en) 2009-02-18
CA2608035A1 (en) 2006-11-16
AU2006244767A1 (en) 2006-11-16
HK1109736A1 (en) 2008-06-20
PT1885380E (pt) 2012-10-11

Similar Documents

Publication Publication Date Title
JP5026408B2 (ja) 泌尿生殖器癌及びその転移の治療を意図した、亜ヒ酸、そのナトリウム塩、及びその誘導体を含む製薬組成物
TW200936182A (en) Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation
KR20140033522A (ko) 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의 나트륨염 및 이것의 유도체를 함유하는 약학 조성물
AU2011224052A1 (en) Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis
HK1109736B (en) Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases
HK1096863A (en) Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
HK1201043A1 (en) Sodium meta arsenite for use in the treatment of pain and/or inflammation associated with cancer
HK1161545A (en) Pharmaceutical compositions comprising of sodium meta-arsenite for use in the treatment of leukemia and lymphoma
Qiu et al. Engineering Manganese-based Immune Amplifier for Chemoimmunotherapy of Peritoneal Metastatic Colorectal Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081202

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120222

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120522

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120620

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150629

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5026408

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees